Welcome to our dedicated page for Sarepta Therapeutics news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics stock.
Sarepta Therapeutics Inc (NASDAQ: SRPT) is a leader in precision genetic medicine, pioneering RNA-targeted therapies for rare neuromuscular and infectious diseases. This dedicated news hub provides investors and healthcare professionals with essential updates on SRPT's scientific advancements, regulatory milestones, and strategic initiatives.
Access real-time press releases covering clinical trial developments, partnership announcements, and financial disclosures. Our curated news collection simplifies tracking SRPT's progress in bringing transformative treatments to underserved patient populations through its proprietary platform technologies.
Key updates include FDA communications regarding novel therapies, research collaborations advancing genetic medicine, and operational developments impacting SRPT's therapeutic pipeline. All content is verified through primary sources to ensure accuracy and timeliness.
Bookmark this page for streamlined access to Sarepta's latest achievements in exon-skipping therapies and gene editing innovations. Stay informed about critical developments shaping this biopharmaceutical innovator's trajectory in targeted genetic treatments.
Sarepta Therapeutics (NASDAQ:SRPT), a precision genetic medicine company focusing on rare diseases, has scheduled its third quarter 2024 financial results announcement for Wednesday, November 6, 2024, after the Nasdaq market closes. The company will host a conference call at 4:30 p.m. ET to discuss the results. The event will be webcast live on Sarepta's investor relations website, with a replay available for one year. Phone participants must register online to receive dial-in details and personal PIN numbers for access.
Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has granted equity awards to 28 new employees hired in September 2024. The awards, approved by the Compensation Committee under the company's 2024 Employment Commencement Incentive Plan, include a total of 23,580 restricted stock units (RSUs). These RSUs will vest over four years, with one-fourth vesting annually on the grant date anniversary, subject to continued employment. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment.
Sarepta, focused on developing treatments for Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), currently has over 40 programs in various stages of development. The company's pipeline is driven by its multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing.
Sarepta Therapeutics (NASDAQ:SRPT) will present new data from its neuromuscular portfolio at the 29th Annual Congress of the World Muscle Society 2024 (WMS 2024) in Prague, Czechia, from Oct. 8-12, 2024.
Highlights include new safety and efficacy results from several studies in the delandistrogene moxeparvovec clinical development program, including Studies 9001-101, 9001-103 (ENDEAVOR), and 9001-301 (EMBARK). Notable presentations are:
- Muscle MRI outcomes in patients with Duchenne Muscular Dystrophy (DMD) treated with delandistrogene moxeparvovec from the EMBARK study on Oct. 12, 2024.
- Long-term safety and tolerability data from phase 1 to phase 3 clinical trials of delandistrogene moxeparvovec on Oct. 11, 2024.
Additional poster presentations cover various aspects of delandistrogene moxeparvovec's safety, efficacy, and functional outcomes over five years. The full WMS 2024 program is available at the event's website.
Sarepta Therapeutics (NASDAQ:SRPT) has appointed Deirdre P. Connelly to its Board of Directors, expanding the board to nine members, with eight being independent. Connelly brings over 30 years of pharmaceutical industry experience, having served as president of North America Pharmaceuticals for GlaxoSmithKline and president of U.S. Pharmaceutical Operations at Eli Lilly. Her extensive background includes executive roles in human resources and pharmaceutical operations.
Currently, Connelly serves on the boards of Macy's and Lincoln Financial Group, and is the Chairperson of the Board at Genmab A/B. This appointment aligns with Sarepta's strategy to deliver transformative therapies for rare diseases, leveraging Connelly's seasoned leadership and industry expertise.
Sarepta Therapeutics (NASDAQ:SRPT) has announced the recipients of its 7th Annual Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year. 25 scholarships have been awarded, including 20 to individuals living with Duchenne muscular dystrophy and 5 to siblings of individuals with Duchenne. Each recipient will receive up to $5,000.
The program, created in 2018, recognizes exceptional individuals pursuing post-secondary education. Recipients are chosen by an independent committee based on community involvement, academic achievements, and personal essays. Since its inception, Sarepta has awarded nearly 140 scholarships through the Route 79 program.
Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, announced equity awards granted on August 30, 2024 under its 2024 Employment Commencement Incentive Plan. Approved by the Compensation Committee of the Board of Directors, these awards serve as a material inducement for 20 new employees hired in August 2024. The awards include a total of 9,290 restricted stock units (RSUs), which will vest annually over four years, contingent on continued employment. Employees did not receive options to purchase shares of Sarepta's common stock. Sarepta focuses on developing treatments for Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs) and has over 40 programs in development.
Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place on September 6, 2024, at 9:15 a.m. E.T. at the New York Marriott Marquis. Senior management will engage in a fireside chat, which will be webcast live on Sarepta's investor relations website and archived for 90 days.
Sarepta focuses on developing precision genetic medicines for rare diseases, particularly Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs). The company currently has over 40 programs in various stages of development, driven by its multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing.
Sarepta Therapeutics (NASDAQ: SRPT) reported strong financial results for Q2 2024, with net product revenues increasing 51% year-over-year to $360.5 million. ELEVIDYS contributed $121.7 million in revenue. The company achieved a GAAP net income of $6.5 million and a non-GAAP net income of $46.7 million. FDA expanded the ELEVIDYS label indication to include patients with Duchenne muscular dystrophy aged 4 and above.
2025 net product revenues are expected to be between $2.9 billion and $3.1 billion. The company will present further data on its SRP-9001 program at the 29th Annual Congress of the World Muscle Society in October 2024. The European Medicines Agency is reviewing the marketing authorization application for ELEVIDYS, with expected approval in 2025.
Roche, Sarepta's partner, will handle commercialization outside the U.S. Additionally, the FDA has granted Fast Track designation to SRP-9003 for limb-girdle muscular dystrophy Type 2E.
Sarepta Therapeutics (NASDAQ: SRPT), a leader in precision genetic medicine, announced equity awards granted as material inducement for employment to 19 new hires in July 2024.
On July 31, 2024, the Compensation Committee approved these awards under the 2024 Employment Commencement Incentive Plan, aligning with Nasdaq Listing Rule 5635(c)(4).
The awards consist of an aggregate of 14,495 restricted stock units (RSUs) that will vest annually over four years, contingent on continuous employment. No stock purchase options were granted.
Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, will release its second quarter 2024 financial results on Wednesday, August 7, 2024, after the Nasdaq Global Market closes. The company will host a conference call at 4:30 p.m. E.T. to discuss the results. Investors can access the webcast live on Sarepta's website, with a replay available for one year. Phone participants must register online to receive dial-in details.
Sarepta focuses on developing treatments for Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), with over 40 programs in various stages of development. The company's pipeline is driven by its multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing.